Procedures
toxicity
DISEASE PROGRESSION
The recommended initial dose of apatinib was 850 mg once daily in 28-day cycles. However, the starting dose was chosen by the investigator based on the patient’s condition. Dose interruption and dose reduction were allowed according to the product label. Treatment continued until disease progression, intolerable toxicity, withdrawal of informed consent, or at the investigators’ discretion. Patients who had progression continued apatinib therapy at the discretion of the investigators.